Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

An expert discusses how medical professionals have integrated tagraxofusp into blastic plasmacytoid dendritic cell neoplasm ...

An international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a ...

Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Targeted alpha therapy: Breakthrough in treating refractory skin cancer. ScienceDaily . Retrieved March 20, 2025 from www.sciencedaily.com / releases / 2025 / 03 / 250312124420.htm ...

Gary A. Ulaner, M.D., Ph.D., F.A.C.N.M. is the director of molecular imaging and therapy at Hoag Family Cancer Institute and ...

SineuGene Therapeutics Co., Ltd. ('SineuGene'), a clinical-stage biotech company pioneering innovative therapies for neurological disorders, today announced that the U.S. Food and Drug Administration ...

In this video, Michael Cecchini, MD, discusses the significance of results from the phase 3 BREAKWATER trial, which were presented at ASCO Gastrointestinal Cancers Symposium.